Onera Health has officially launched its Polysomnography-as-a-Service solution, for the diagnosis of sleep disorders, in Europe.
The new sleep diagnostics solution combines a patch-based sensor system with cloud technology to allow healthcare professionals to perform polysomnography anywhere and anytime.
The end-to-end solution is designed for in-lab and at-home sleep diagnostics and monitoring.
Without the need for upfront investment, it requires minimal effort for sleep studies to be conducted with maximum comfort and convenience in patients’ homes.
It uses the companies’ US Food and Drug Administration (FDA)-approved and CE-marked Onera Sleep Test System (STS) along with the Onera Digital Health Platform.
The Onera STS sensors are used to capture all the signals required for polysomnography.
Medical-grade sleep data is captured by four sensors, which are applied to the forehead, upper chest, abdominal area and lower leg using patches.
These no-wire sensors provide a complete polysomnography signal set that includes electroencephalogram (EEG), electromyography (EMG), electrooculography (EOG) and electrocardiogram (ECG).
Additionally, sound pressure (to detect snoring), respiratory measurements, body motion and body position, and electromyography leg data are also collected.
The Onera Digital Health Platform manages the data, securely directing it within the networks of clinics and providers.
Onera Health CEO Ruben de Francisco said: “For many years, comprehensive sleep diagnostics was mainly possible in in-patient laboratories that required significant resources, resulting in long waiting times and often poor patient experience.
“Our innovative solution enables large-scale utilisation of at-home polysomnography.
“This will not only increase patient comfort during a sleep study significantly, it will also improve access and shorten the diagnostic journeys of patients suffering from sleep disorders.”
The company stated that the new sleep diagnostics solution will be available in Germany and The Netherlands this year, with plans for its launch in other European countries to follow.